Our flagship strategy

We invest in the most promising biopharmaceutical and medical device start-ups that address pressing unmet clinical needs and aim to transform patients’ lives.

Capital X, the 10th iteration of our flagship fund, is the largest healthcare fund dedicated to early-stage investments and company creation in Europe.

Close	Fund	AMT
2008	Sofinnova Capital VI	€260 million
2012	Sofinnova Capital VII	€240 million
2015	Sofinnova Capital VIII	€300 million
2018	Sofinnova Capital IX	€333 million
2021	Sofinnova Capital X	€472 million

Close: 2008
Fund: Sofinnova Capital VI
AMT: €260 million
Close: 2012
Fund: Sofinnova Capital VII
AMT: €240 million
Close: 2015
Fund: Sofinnova Capital VIII
AMT: €300 million
Close: 2018
Fund: Sofinnova Capital IX
AMT: €333 million
Close: 2021
Fund: Sofinnova Capital X
AMT: €472 million

“I've wanted to be in biotech since I was 16 years old. It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me.”

“I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”